RT Journal Article
T1 Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases.
A1 Levivien, Clara
A1 Bottois, Cecile
A1 Lopez Medina, Clementina
A1 Dumas, Sophie
A1 Hubert, Julien
A1 Belo, Sephora
A1 Roux, Christian
A1 Conort, Ornella
A1 Dougados, Maxime
K1 Biologic disease-modifying anti-rheumatic drugs
K1 Biosimilar pharmaceuticals
K1 Clinical pharmacist
AB Despite several studies proving the efficacy and safety of biosimilars compared with original drugs, switching to a biosimilar remains challenging when the decision is at the discretion of physicians with mandatory consent from patients. Educating patients about biosimilars seems important to increase the prescription rate of biosimilars. This study aimed to evaluate the impact of a clinical pharmacist consultation on the switch to and retention rate of a biosimilar for patients with inflammatory rheumatic diseases. This retrospective study compared 2 groups of adult patients receiving (intervention) or not (control) a consultation with a pharmacist right before the rheumatologist consultation. The primary outcome was the frequency of patients who switched to a biosimilar at the end of the rheumatologist visit. We analysed 141 patients (50% women, 50±15years old, on original adalimumab (62%) or etanercept (38%)) who had never used biosimilars: 85 in the intervention group and 56 in the control group. The switch rate to a biosimilar significantly differed between the groups: 69.4% versus 41.1% in the intervention group versus the control group respectively (P This study highlights the positive impact of a pharmacist consultation before the physician's one on switching to a biosimilar, but more studies are needed to assess the impact of this pharmacist consultation on preventing the nocebo effect and therefore on improving the retention rate of biosimilars.
PB Elsevier
YR 2021
FD 2021-11-25
LK http://hdl.handle.net/10668/22291
UL http://hdl.handle.net/10668/22291
LA en
NO Levivien C, Bottois C, López Medina C, Dumas S, Hubert J, Belo S, et al. Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases. Joint Bone Spine. 2022 May;89(3):105322
DS RISalud
RD Apr 17, 2025